Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs SEATTLE, Oct. 1, 2025 ...

SEATTLE, March 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and ...

SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, ...

Atossa Therapeutics, Inc. announced the granting of a new patent (U.S. Patent No. 12,275,684) by the USPTO for its enteric oral formulations of (Z)-endoxifen, a potent Selective Estrogen Receptor ...

SEATTLE, Oct. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer ...

Atossa Therapeutics, Inc. has provided a shareholder update highlighting significant progress in their clinical programs, particularly with their therapy (Z)-endoxifen for breast cancer prevention and ...

Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (ATOS) (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has ...

SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 ...

Veteran development leader with successful regulatory approvals record returns to lead late-stage clinical and regulatory programs to address multiple unmet clinical needs "Janet's extensive ...

SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has requested a Type C meeting with the U.S. Food and Drug Administration ...